E. M. Guerra Alía

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

F. Marmé, I. Vergote, S. Pignata, 2019, The New England journal of medicine.

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

E. G. Guerra Alía, J. Galindo Álvarez, Cayetano Sempere Ortega, 2019, Case Reports in Oncology.

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

M. Mouret-Reynier, N. Colombo, A. Floquet, 2021, Gynecologic oncology.

Survival with Cemiplimab in Recurrent Cervical Cancer.

B. Monk, Chih-Long Chang, S. Lheureux, 2022, The New England journal of medicine.

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

B. Monk, K. Yonemori, I. Ray-Coquard, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.